No Image Provided

NuVision Biotherapies

VC Funding

Series A

Healthcare & Biotech Published 9 March 2023

Summary

In a significant market movement during March 2023, NuVision Biotherapies was the subject of a vc funding. The transaction achieved a gross valuation of £1,100,000. Leading the round was University of Nottingham, Mercia’s EIS Funds, Midlands Engine Investment Fund, MEIF Proof of Concept & Early Stage Fund, Pioneer Group.

This transaction was brokered by an undisclosed advisor. The deal reflects ongoing market confidence within its sector.

Lead Investor / Acquirer

University of Nottingham

Lead Investor / Acquirer

Mercia’s EIS Funds

Lead Investor / Acquirer

Midlands Engine Investment Fund

Lead Investor / Acquirer

MEIF Proof of Concept

Lead Investor / Acquirer

Early Stage Fund

Lead Investor / Acquirer

Pioneer Group

Advising Broker

Undisclosed Firm

Related Deals in Healthcare & Biotech

Series A prioritised

VC Funding

Newcells Biotech

£2,350,000

Feb 2024

VC Funding

HutanBio

£2,250,000

Jan 2024

VC Funding

Lottie

£17,253,062

Oct 2023

VC Funding

Skin Analytics

£4,000,000

Sept 2020

View Company Details

Financials, officers, full deal history

Original Source

This funding round is sourced from the Tech.eu Funding Explorer. View the full record, investors, and citations there.

View on Tech.eu Funding Explorer

Funding data via Tech.eu Funding Explorer, licensed under CC BY 4.0. See our methodology.

AI Insight Lenses

Pro

AI-generated analysis from four professional perspectives. Powered by PE Deals.

Free to all registered users.